

Company Sponsored Research  
Update Note  
04/25/2019

# Orgenesis Inc. (NASDAQ: ORGS)

## New Facility Set to Dramatically Expand Production Capability

### Investment Highlights:

- **Orgenesis announced plans to launch a new facility for cell and gene therapy commercial manufacturing on March 25<sup>th</sup>, 2019.** The Company signed a lease agreement for a 61,354 square foot plant located in Belgium for its Masthercell Global subsidiary to manufacture cell and gene therapy commercial products. The new facility will be fully upgraded with state-of-the-art equipment to maximize production efficiency and is *expected to triple Masthercell Global's current capacity once operational in 2021*. With this new production plant, Masthercell Global will become the first cell and gene therapy Contract Development and Manufacturing Organization (CDMO) in Europe with a specific location for large scale manufacturing. We believe this new commercial facility will allow the Company to expand its global presence and customer base, and benefit from the exceptional talent in Belgium where Orgenesis will create hundreds of new jobs.
- **Orgenesis announced collaboration with Digilab to co-develop cell printing capabilities on April 4<sup>th</sup>, 2019.** The Company aims to utilize Digilab's 3D printing technology to automate the production of live cellular structures and tissues for its cell and gene therapy applications, which is likely to transform the whole cell therapeutics service industry with broad uses such as stem cell application and customized cell arrays. We view this partnership as a strong progression in Orgenesis' goal of developing leading technologies to enable cell and gene therapy applications.

### Company Description

Orgenesis Inc. engages in cell therapy development and manufacturing for advanced medicinal products. The company aims to provide the pathway for Advanced Therapy Medicinal Products (ATMPs) from research to patients worldwide.

### Biotechnology

Hunter Diamond, CFA  
Vivian Zhang (Equity Research Associate)  
[research@diamondequityresearch.com](mailto:research@diamondequityresearch.com)  
1120 Avenue of Americas, 4th Floor New York, NY

### Price- Volume History



### Key Statistics

|                                  |                |
|----------------------------------|----------------|
| Closing Price (As of 04/24/2019) | \$4.55         |
| 52 Week Range                    | \$3.87-\$10.49 |
| Average Daily Volume             | 38,285         |
| Shares Outstanding (M)           | 15.62          |
| Market Capitalization (M)        | 71.08          |
| Number of Analysts Covering      | 2              |
| Enterprise Value/Revenue         | 4.84x          |

### Revenue(\$ in millions)

| Dec. FY | 2017A  | 2018A  | 2019E  |
|---------|--------|--------|--------|
| 1Q      | 1.85A  | 2.64A  | 4.22E  |
| 2Q      | 2.30A  | 3.99A  | 6.38E  |
| 3Q      | 2.56A  | 6.23A  | 9.97E  |
| 4Q      | 3.38A  | 5.80A  | 12.09E |
| FY      | 10.09A | 18.66A | 32.66E |

### EPS(\$)

| Dec. FY | 2017A   | 2018A   | 2019E   |
|---------|---------|---------|---------|
| 1Q      | (0.55)A | (0.52)A | (0.29)E |
| 2Q      | 0.02A   | (0.20)A | (0.05)E |
| 3Q      | (0.02)A | (0.35)A | (0.05)E |
| 4Q      | (0.41)A | (0.63)A | (0.21)E |
| FY      | (1.08)A | (1.43)A | (0.60)E |

## Disclosures

Diamond Equity Research, LLC has created and distributed this report. This report is based on information we consider reliable, including the subject of the report, but have not been provided any non-public information. This report does not explicitly or implicitly affirm that the information contained within this document is accurate and/or comprehensive, and as such should not be relied on in such a capacity. All information contained within this report is subject to change without any formal or other notice provided. Diamond Equity Research, LLC is not a FINRA registered broker/dealer or investment adviser and does not provide investment banking services and follows customary internal trading procedures pending the release of the report found on [disclosure page](#).

This document is not produced in conjunction with a security offering and is not an offering to purchase securities. This report does not consider individual circumstances and does not take into consideration individual investor preferences. Recipients of this report should consult professionals around their personal situation, including taxation. Statements within this report may constitute forward-looking statements, these statements involve many risk factors and general uncertainties around the business, industry, and macroeconomic environment. Investors need to be aware of the high degree of risk in micro capitalization equities.

Diamond Equity Research LLC is being compensated by Orgenesis Inc. for producing research materials regarding Orgenesis Inc. and its securities, which is meant to subsidize the high cost of creating the report and monitoring the security, however the views in the report reflect that of Diamond Equity Research. All payments are received upfront and are billed for an annual or semi-annual research engagement. As of 04/25/2019, the issuer had paid us \$24,500 for our services, which commenced 07/07/2017 and were billed either annually or semi-annually. Diamond Equity Research LLC may be compensated for non-research related services, including presenting at Diamond Equity Research investment conferences, press releases and other additional services. The non-research related service cost is dependent on the company, but usually do not exceed \$5,000. The issuer has paid us \$500 for presenting at an investment conference as of 04/25/2019. Issuers are not required to engage us for these additional services. Additional fees may have accrued since then.

Diamond Equity Research, LLC, its subsidiaries, and employees may currently have or open a long/short equity position of the shares of the subject company in this report. Diamond Equity Research, LLC is not a registered broker dealer and does not conduct investment banking or receive commission sharing revenue arrangements related to the subject company of the report. The price per share and trading volume of subject company and companies referenced in this report may fluctuate and Diamond Equity Research, LLC is not liable for these inherent market fluctuations. The past performance of this investment is not indicative of the future performance, no returns are guaranteed, and a loss of capital may occur. Certain transactions, such as those involving futures, options, and other derivatives, can result in substantial risk and are not suitable for all investors.

Photocopying, duplicating or otherwise altering or distributing Diamond Equity Research, LLC reports is prohibited without explicit written permission. This report is disseminated primarily electronically and is made available to all recipients. Additional information is available upon request. For further questions, please contact [research@diamondequityresearch.com](mailto:research@diamondequityresearch.com)